Robotic Lobectomy
Lung Cancer Surgery, London

What Is a
Lobectomy?

The lung has five lobes — three on the right, two on the left. A lobectomy removes one lobe in its anatomical entirety, including its dedicated blood vessels, airway, and the draining mediastinal lymph nodes. It removes approximately 15–20% of total lung volume.

The operation is not simply about removing tumour. The mediastinal lymph node dissection integral to a lobectomy determines how the cancer is staged — and whether adjuvant chemotherapy, immunotherapy, or targeted therapy is recommended after surgery. A lobectomy done without thorough nodal clearance may cure the primary tumour while leaving the patient understaged and undertreated.

This is why the quality of a lobectomy is not determined by the incision alone. It is determined by the completeness of the dissection — and the robotic platform's mediastinal access is where that difference is made. Robotic lung surgery overview →

USA · 1995

LCSG 821

Ginsberg & Rubinstein · Annals of Thoracic Surgery · 1995 · 247 patients randomised

The Lung Cancer Study Group randomised 247 patients to lobectomy versus sublobar resection for T1N0 non-small cell lung cancer. Sublobar resection was associated with a threefold higher rate of local recurrence and a trend toward worse survival. Lobectomy was established as the anatomical minimum for primary lung cancer.

This remained the definitive evidence for nearly thirty years. The question it settled — lobectomy versus lesser resection — is now revisited only for specific small tumours where JCOG0802 and CALGB 140503 have established segmentectomy as equivalent. For everything else, Ginsberg still applies.

Denmark · 2016

The Danish RCT

Bendixen et al. · Lancet Oncology · 2016 · 503 patients randomised

The first randomised controlled trial comparing VATS lobectomy against open thoracotomy. VATS demonstrated significantly better post-operative quality of life at two weeks, one month, and three months. Pain scores lower. Return to normal activity faster. Oncological outcomes equivalent. Keyhole access was established as the preferred route.

Open thoracotomy — spreading the ribs to access the lung — was not the standard of care for routine lobectomy after 2016. For patients choosing where to have surgery, this distinction remains clinically material.

United Kingdom

VIOLET

Lim et al. · NEJM Evidence · 2022;1(3):EVIDoa2100016 · UK multicentre RCT · 656 patients

The UK’s own randomised controlled trial of VATS versus open lobectomy, led by Mr Eric Lim at Royal Brompton Hospital across multiple UK centres. The primary outcome was patient-reported physical function at five weeks — the first RCT to measure recovery as patients themselves experience it, not just clinical endpoints. VATS patients reported significantly better physical function, less pain, and fewer complications. Oncological outcomes were equivalent. A 2023 editorial in the Journal of Thoracic and Cardiovascular Surgery described VIOLET as setting keyhole surgery as “the standard for surgical treatment of early-stage lung cancer.”

Two randomised trials in two countries had now established the same conclusion. The question was no longer whether to operate through small incisions — it was which instrument provides the best view and control through them.

Now

The Robotic Era

Institutional series · RAVAL trial (ongoing) · SCTS national data

A definitive RCT comparing robotic versus VATS lobectomy is ongoing (RAVAL). What existing series consistently show: higher mediastinal lymph node yield with robotic dissection, lower conversion rates to open in complex cases, and greater facility with post-chemoimmunotherapy anatomy where tissue planes are scarred. The SCTS national data shows robotic adoption concentrated at high-volume centres.

The staging benefit of thorough nodal dissection — not just the incision size — is where the robotic platform is making its most defensible oncological argument.

The JCOG0802 and CALGB 140503 trials restricted evidence for segmentectomy to tumours of 2cm or less. For T1c (greater than 2cm, up to 3cm) and T2 tumours, lobectomy provides superior local cancer control. Tumour size is the single most important determinant of which anatomical resection is appropriate.

Tumours close to the main airway, hilar vessels, or spanning segmental boundaries cannot be removed with adequate oncological margins by segmentectomy — the intersegmental plane does not accommodate the tumour's position. For these cases, the lobar unit is the correct anatomical boundary of resection.

Where lymph nodes within the lung lobe are involved — N1 disease — lobectomy with formal mediastinal node dissection is the standard of care. Segmentectomy does not deliver equivalent nodal clearance for N1 disease. Occasionally, a planned segmentectomy is upgraded to lobectomy intraoperatively when nodal involvement is identified. This is expected clinical practice, not a complication.

The Lymph Node
Question

Lobectomy is often described as removing a lobe of the lung. That is technically accurate but clinically incomplete. The operation has a second, equally important component: systematic dissection and removal of the mediastinal lymph nodes — the nodes in the centre of the chest that drain the affected lobe.

This dissection serves two purposes that are inseparable from the cancer outcome. First, it removes routes of microscopic spread adjacent to the primary tumour. Second — and this is the part that determines much of what happens next — it provides the accurate pathological staging on which all subsequent treatment decisions are made.

Whether a patient is offered adjuvant chemotherapy, immunotherapy such as pembrolizumab, or targeted therapy such as osimertinib for EGFR-positive disease after surgery depends critically on whether the nodal staging is accurate. If nodes are sampled rather than dissected, the staging may be wrong. If the staging is wrong, the treatment plan built upon it may be wrong.

Robotic mediastinal access — with magnified 3D vision and wristed instruments that can reach nodal stations that VATS instruments access less systematically — is where the oncological argument for the platform is strongest.

Dr Okiror practises privately at London Bridge Hospital and The Lister Hospital Chelsea, drawing on the clinical background of his NHS base at Guy’s and St Thomas’ — one of the highest-volume thoracic surgery centres in the UK, performing approximately one in eight of all lung cancer operations nationally.

At GSTT, over 70% of primary lung cancer anatomic resections are now performed robotically, against a national average of approximately 24% (SCTS 2024–25). Operative mortality in primary cancer surgery is 0.41% — materially below the national benchmark of approximately 1.5% reported by the NLCA. These are published figures from the national audit, not internal claims.

As Clinical Audit Lead for Thoracic Surgery, Dr Okiror is responsible for the submission and verification of that data. He is, in that role, the person most directly accountable for its accuracy — and most precisely aware of what it does and does not show.

Dr Okiror performed his first robotic lobectomy in August 2020. His personal robotic case series has grown every year since, and now spans lobectomy, segmentectomy, sleeve resection, and post-chemoimmunotherapy cases. His personal operative data includes a median robotic console time of 84 minutes across his case series — a measure of operative consistency and efficiency that is as relevant to patient outcomes as incision size. Full data is available at consultation.

The same approach he uses in NHS practice is the approach applied to private patients at London Bridge Hospital and The Lister Chelsea. Private patients do not access a diluted or occasional service — they access the same operative technique, the same mediastinal dissection, and the same MDT discussion that governs every case.

One specific difference at high-volume robotic centres is visible in pneumonectomy rates. At GSTT, the proportion of anatomic resections requiring pneumonectomy has fallen from 3.7% to 1.5% over seven years — a halving that reflects the growing technical capability to complete difficult hilar dissections at lobectomy level, without escalating to whole-lung removal.

The Screening Era
Changed Who Needs a Lobectomy

Lung cancer surgery used to be dominated by patients with symptomatic disease — patients who had presented with cough, weight loss, or breathlessness, by which point the tumour was typically large and the patient was often older with significant comorbidities. Open thoracotomy, with its longer recovery, was the only option available. These patients had limited reserves to draw on during that recovery.

The NHS Targeted Lung Health Check programme is changing who is presenting with lung cancer. Five-year programme data published in Nature Medicine in March 2026 shows that over 75% of screen-detected cancers are diagnosed at Stage I or II. Many of these patients are found incidentally — they may be in their 50s or early 60s, still working, and without symptoms. They want to know that the operation can be done through small incisions and that they will be back to normal within weeks, not months.

The screening-era lobectomy patient is precisely the patient who benefits most from robotic keyhole access — because they have the most to lose from a prolonged recovery from open surgery, and the most to gain from returning to their normal life quickly and completely. Targeted lung health check →

For tumours of 2cm or less, with no PET-CT evidence of nodal involvement, segmentectomy is now evidence-based and achieves equivalent cancer control with significantly more lung preserved. If this option has not been discussed, it is worth asking whether the tumour size and location were reviewed against this threshold. Not every patient with a lobectomy recommendation has had that conversation.

Open thoracotomy is not the standard of care for routine lobectomy at high-volume centres. If you have been told open surgery is necessary, asking about the conversion rate from planned keyhole to open at that specific centre is a reasonable question. Nationally, robotic adoption varies widely — 71% of anatomic resections at some centres versus single-digit percentages at others (SCTS 2024–25). The approach offered often reflects what a centre routinely does, not what your tumour requires.

Nodal sampling and systematic nodal dissection are not the same procedure. The distinction affects staging accuracy, and staging accuracy affects what treatment is recommended after surgery. Asking which nodal stations will be dissected — and what happens to the adjuvant treatment plan if any are positive — is a clinically relevant question, not a technical one. A surgeon who has considered this carefully will be able to answer it precisely.

Before you commit

For tumours of 2cm or less in the periphery of the lung, with no evidence of nodal involvement on PET-CT, a lung-sparing segmentectomy now achieves equivalent cancer control — with significantly more healthy lung preserved. At consultation, Dr Okiror reviews whether this applies before recommending any operation.